Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;47:646-647
Published online before print March 6, 2006, doi: 10.1161/01.HYP.0000209579.56979.a0
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/4/646    most recent
01.HYP.0000209579.56979.a0v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flack, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flack, J. M.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Blood Pressure Medicines
*High Blood Pressure
Related Collections
Right arrow Clinical Studies
Right arrowRelated Article

(Hypertension. 2006;47:646.)
© 2006 American Heart Association, Inc.


Editorial Commentaries

Noninvasive Hemodynamic Measurements

An Important Advance in Individualizing Drug Therapies for Hypertensive Patients

John M. Flack

From the Department of Internal Medicine, Division of Endocrinology, Metabolism, and Hypertension, Wayne State University School of Medicine and the Detroit Medical Center, Detroit, Mich.

Correspondence to John M. Flack, Department of Internal Medicine, Wayne State University School of Medicine, University Health Center, 2E-UHC, Detroit, MI 48201. E-mail jflack@med.wayne.edu


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

It has been well established that effective blood pressure (BP) lowering, using various antihypertensive agents with different mechanisms of action, lowers the risk for cardiovascular morbidity and mortality.1–4 However, when hypertensive populations are partitioned into subgroups by race, sex, geography, and age, differences in BP responses to single antihypertensive drugs emerge, albeit at the group level, that have been used to guide therapy for individuals within these contrasted groups.1,5,6 With respect to race, perhaps the most widely used group characteristic used to guide individual therapy, we5 and Sehgal6 have argued that the observed racial differences in BP response overlap to such a large degree that, by far, the greatest source of variation in BP response is within rather than between groups. This observation renders the use of group characteristics as grossly suboptimal criterion on which to base therapy for all individuals of a group. The inaccuracy of blanket extrapolation of group characteristics to predict BP responses for individuals is also likely to be true for traits such as geographic residence, age, and sex.

Thus, the findings reported by Smith et al7 in this issue of Hypertension were very encouraging. These investigators showed that consideration of hemodynamic parameters, as determined noninvasively by impedance cardiography (IC) (BioZ, Cardiodynamics), in the selection of antihypertensive therapy in primary care practice settings improved rates of BP control and normalization of selected hemodynamic parameters in drug-treated hypertensives with BP >140/90 mm Hg. They used sequential measurement of hemodynamic parameters to guide the selection of antihypertensive drug . . . [Full Text of this Article]


Related Article:

Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects
Ronald D. Smith, Pavel Levy, Carlos M. Ferrario for the Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group
Hypertension 2006 47: 771-777. [Abstract] [Full Text] [PDF]